title: (L)-2-oxothiazolidine-4-carboxylate in the treatment of primary hyperoxaluria type 1.
abstract: OBJECTIVE
  To evaluate the short-term efficacy of (l)-2-oxothiaolidine-4-carboxylate (OTZ, which reduces urinary oxalate excretion in normal subjects) in the treatment of primary hyperoxaluria type 1 (PH1) in a phase II study.
  
  
  METHODS
  Two patients with PH1 received intravenous infusions of OTZ (100 mg/kg body weight for 2 h) given every 8 h for four doses. One patient also received a placebo treatment. Urine samples (24-h collections) were obtained before and during OTZ treatment and assayed for oxalate, citrate, creatinine, sulphate and pH. Daily blood samples were assayed for plasma oxalate and serum creatinine.
  
  
  RESULTS
  Urinary oxalate excretion was unaffected by OTZ treatment. Plasma oxalate declined in both individuals with OTZ treatment, but the effect was small. Plasma cysteine was normal in one patient, rising from a mean (sd) of 36 (3.7) micromol/L before treatment to a peak of 141 micromol/L after OTZ, but was not detected in samples from the other patient. The ratio of oxalate to creatinine clearances was high in both patients, with mean values of 3.1 and 3.8.
  
  
  CONCLUSIONS
  Treatment with OTZ did not lead to clinically significant changes in urinary oxalate excretion. The high clearance of oxalate in these patients suggests a substantial renal secretion of oxalate.
authors.affiliation: Department of Urology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.
authors.forename: R P
authors.initials: RP
authors.lastname: Holmes
authors.forename: D G
authors.initials: DG
authors.lastname: Assimos
authors.forename: D M
authors.initials: DM
authors.lastname: Wilson
authors.forename: D S
authors.initials: DS
authors.lastname: Milliner
mesh_terms: D002129:Calcium Oxalate / Q000652:urine; D002136:Calcium, Dietary; D003545:Cysteine / Q000097:blood; D005260:Female; D006801:Humans; D006960:Hyperoxaluria, Primary / Q000097:blood / Q000188:drug therapy* / Q000652:urine; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D011761:Pyrrolidonecarboxylic Acid; D013844:Thiazoles / Q000008:administration & dosage*; D053778:Thiazolidines; D016896:Treatment Outcome
chemical_list: D002136:Calcium, Dietary; D013844:Thiazoles; D053778:Thiazolidines; D002129:Calcium Oxalate; D003545:Cysteine; D011761:Pyrrolidonecarboxylic Acid; C029536:2-oxothiazolidine-4-carboxylic acid